StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30285% above fair value
$144.46−3.30 (-2.23%)

Close on Nov 16, 2026Market cap $356.41BP/E 115.6Yield 2.27%

Merck r&d expenses

Research and development expenses are spending on new products and technology.

Merck's R&D Expenses for the twelve months ending Jun 30, 2026 was $30.45B, up 68.1% year over year. For fiscal 2025 it was $15.79B, down 12.0% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $30.53B in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.79B-12.0%
FY2024Dec 31, 2024$17.94B-41.2%
FY2023Dec 31, 2023$30.53B+125.4%
FY2022Dec 31, 2022$13.55B+10.6%
FY2021Dec 31, 2021$12.25B-8.6%
FY2020Dec 31, 2020$13.40B+37.8%
FY2019Dec 31, 2019$9.72B-0.3%
FY2018Dec 31, 2018$9.75B-5.7%
FY2017Dec 31, 2017$10.34B+0.8%
FY2016Dec 31, 2016$10.26B+53.1%
FY2015Dec 31, 2015$6.70B-6.6%
FY2014Dec 31, 2014$7.18B-4.3%
FY2013Dec 31, 2013$7.50B-8.1%
FY2012Dec 31, 2012$8.17B-3.5%
FY2011Dec 31, 2011$8.47B-23.8%
FY2010Dec 31, 2010$11.11B+90.1%
FY2009Dec 31, 2009$5.85B+21.6%
FY2008Dec 31, 2008$4.81B-1.6%
FY2007Dec 31, 2007$4.88B–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.74B+140.6%
Q1 FY2026Mar 31, 2026$12.59B+247.7%
Q4 FY2025Dec 31, 2025$3.89B-15.2%
Q3 FY2025Sep 30, 2025$4.23B-27.8%
Q2 FY2025Jun 30, 2025$4.05B+15.7%
Q1 FY2025Mar 31, 2025$3.62B-9.3%
Q4 FY2024Dec 31, 2024$4.58B-52.4%
Q3 FY2024Sep 30, 2024$5.86B+77.3%
Q2 FY2024Jun 30, 2024$3.50B-73.7%
Q1 FY2024Mar 31, 2024$3.99B-6.6%
Q4 FY2023Dec 31, 2023$9.63B+155.0%
Q3 FY2023Sep 30, 2023$3.31B-24.8%
Q2 FY2023Jun 30, 2023$13.32B+376.1%
Q1 FY2023Mar 31, 2023$4.28B+66.0%
Q4 FY2022Dec 31, 2022$3.78B+23.0%
Q3 FY2022Sep 30, 2022$4.40B+79.9%
Q2 FY2022Jun 30, 2022$2.80B-35.2%
Q1 FY2022Mar 31, 2022$2.58B+6.8%
Q4 FY2021Dec 31, 2021$3.07B-47.0%
Q3 FY2021Sep 30, 2021$2.45B-27.0%
Q2 FY2021Jun 30, 2021$4.32B+107.2%
Q1 FY2021Mar 31, 2021$2.41B+9.2%
Q4 FY2020Dec 31, 2020$5.79B+141.2%
Q3 FY2020Sep 30, 2020$3.35B+4.5%
Q2 FY2020Jun 30, 2020$2.09B-4.8%
Q1 FY2020Mar 31, 2020$2.21B+14.4%
Q4 FY2019Dec 31, 2019$2.40B+8.4%
Q3 FY2019Sep 30, 2019$3.20B+54.9%
Q2 FY2019Jun 30, 2019$2.19B-3.7%
Q1 FY2019Mar 31, 2019$1.93B-39.6%
Q4 FY2018Dec 31, 2018$2.21B-4.4%
Q3 FY2018Sep 30, 2018$2.07B-53.1%
Q2 FY2018Jun 30, 2018$2.27B+27.6%
Q1 FY2018Mar 31, 2018$3.20B+74.6%
Q4 FY2017Dec 31, 2017$2.32B-51.6%
Q3 FY2017Sep 30, 2017$4.41B+165.2%
Q2 FY2017Jun 30, 2017$1.78B–
Q1 FY2017Mar 31, 2017$1.83B–
Q4 FY2016Dec 31, 2016$4.79B–
Q3 FY2016Sep 30, 2016$1.66B–

More Merck figures

See a number that looks wrong?